Clinical Trials on Diffuse Large Cell Lymphoma in China

Total 1046 results

Qian Wenbin

Not yet recruiting

Sintilimab Plus R-GemOx as Second-line Salvage Therapy in Patients With R/R DLBCL

Diffuse Large B Cell Lymphoma | Refractory Diffuse Large B-Cell Lymphoma | Relapsed Diffuse Large B-Cell Lymphoma

China
Zhejiang University
Shanghai First Song Therapeutics Co., Ltd

Not yet recruiting

An Exploratory Clinical Study Evaluating the Safety and Efficacy of Anti CD30 CAR T Cells in Patients With CD30+ Relapsed/Refractory Lymphoma

Hodgkin Lymphoma | Anaplastic Large Cell Lymphoma | Angioimmunoblastic T-cell Lymphoma | Diffuse Large B Cell Lymphoma | Gray Zone Lymphoma | NK/T Cell Lymphoma | Peripheral T Cell Lymphoma, Unspecified | Mediastinal B-Cell Diffuse Large Cell Lymphoma

China
Beijing Yongtai Ruike Biotechnology Company Ltd

Recruiting

Phase I Clinical Trial of RC19D2 Cell Injection in the Treatment of Diffuse Large B-cell Lymphoma

Recurrent Diffuse Large B-Cell Lymphoma | Refractory Diffuse Large B-cell Lymphoma

China
RenJi Hospital

Recruiting

Zanubrutinib+Lenalidomide+R-ICE in Relapsed/Refractory DLBCL

Diffuse Large B-cell Lymphoma Recurrent | Diffuse Large B Cell Lymphoma Refractory

China
Zhejiang Cancer Hospital

Recruiting

A-RGEMOX in the Treatment of Early Relapsed/Refractory DLBCL

Diffuse Large B-cell Lymphoma Recurrent | Diffuse Large B Cell Lymphoma Refractory

China
The First Affiliated Hospital with Nanjing Medical...

Unknown

Lenalidomide, Rituximab, Gemcitabine, Oxaliplatin and Dexamethasone in Relapse and Refractory DLBCL (R2-GOD)

Diffuse Large B-cell Lymphoma Recurrent | Diffuse Large B Cell Lymphoma Refractory

China
Ruijin Hospital
The First Affiliated Hospital with Nanjing Medical University; Shanxi Province... and other collaborators

Not yet recruiting

A Retrospective Study on Extranodal Lymphoma or Lymphoma of Rare Pathological Types

Lymphoma | Marginal Zone Lymphoma | Anaplastic Large Cell Lymphoma | Angioimmunoblastic T-cell Lymphoma | Diffuse Large B Cell Lymphoma | Mucosa-Associated Lymphoid Tissue Lymphoma | Intravascular Large B-Cell Lymphoma | Extranodal Lymphoma | NK/T-Cell Lymphoma, Nasal and Nasal-Type

China
Beijing Tongren Hospital

Recruiting

CD19/CD22 Bispecific CAR-T Cell Therapy for Relapsed/Refractory B-cell Lymphoma or Acute Lymphoblastic Leukemia

B-cell Lymphoma | Diffuse Large B Cell Lymphoma | B-cell Acute Lymphoblastic Leukemia

China
Peking University People's Hospital
Peking University Cancer Hospital & Institute

Recruiting

Frontline of ASCT in High-risk DLBCL (Essential)

Diffuse Large B Cell Lymphoma

China
Changhai Hospital
Nanjing Enricnk Biotech Co., Ltd

Recruiting

The Study of Anti-CD19 CAR NK Cells in the Treatment of Relapsed/Refractory Diffuse Large B Cell Lymphoma

Diffuse Large B Cell Lymphoma

China
Ruijin Hospital

Recruiting

Mechanism of Resistance to GNC-038 in Relapsed and Refractory Diffuse Large B-cell Lymphoma

Diffuse Large B Cell Lymphoma

China
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Not yet recruiting

A Study of Anlotinib Hydrochloride Capsules in Subjects With Diffuse Large B-Cell Lymphoma

Diffuse Large B-cell Lymphoma

China
Ruijin Hospital

Active, not recruiting

Zanubrutinib, Lenalidomide and Rituximab (ZR2) in Elderly Treatment-naive Patients With Diffuse Large B-cell Lymphoma (DLBCL)

Diffuse Large B Cell Lymphoma

China
Ruijin Hospital

Active, not recruiting

Study Evaluating the Safety and Efficacy of iR2 in Untreated and Unfit Elderly Patients With DLBCL

Diffuse Large B Cell Lymphoma

China
Innovent Biologics (Suzhou) Co. Ltd.

Completed

A Study Comparing the Efficacy and Safety Between I-CHOP and R-CHOP in Untreated CD20-Positive Diffuse Large B-cell Lymphoma Patients

Diffuse, Large B-Cell, Lymphoma

China
Fudan University

Terminated

Dose-adjusted EPOCH-R in MYC Positive DLBCL

Diffuse Large B-cell Lymphoma

China
Fudan University

Unknown

Interim PET/CT Guided Cycle Numbers of R-CHOP in DLBCL

Diffuse Large B-cell Lymphoma

China
Yan Zhang, MD
Peking University First Hospital; Chinese PLA General Hospital; Peking University...

Recruiting

Pola-R2 in Newly Diagnosed Non-fit Elderly DLBCL Patients

Diffuse Large B Cell Lymphoma

China
Peng Liu

Recruiting

Prospective Clinical Study of ZPR Regimen in Elderly Treatment-naive Diffuse Large B-cell Lymphoma

Diffuse Large B Cell Lymphoma

China
Zhao Weili

Not yet recruiting

A Real-world Study of Tafasitamab in Combination With Lenalidomide in Patients withR/R DLBCL

Diffuse Large B-cell Lymphoma

China
Ruijin Hospital

Recruiting

A Combination Study of CAR-T Therapy in r/r B-NHL

Diffuse Large B Cell Lymphoma

China
Ruijin Hospital
Shanxi Province Cancer Hospital; The First Affiliated Hospital of Anhui Medical... and other collaborators

Recruiting

Genotype-guided Treatment in DLBCL

Diffuse Large B Cell Lymphoma

China
Ruijin Hospital

Recruiting

Novel Targeted Drugs Combined With R-ICE Regimen in Relapsed and Refractory Diffuse Large B-cell Lymphoma (R-ICE+X)

Diffuse Large B Cell Lymphoma

China
Ruijin Hospital

Recruiting

The Safety and Effectiveness of 4R-CHOP+4R vs 6R-CHOP+2R in Newly Diagnosed Patients With DLBCL in Low Risk

Diffuse Large B Cell Lymphoma

China
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Recruiting

A Study of TQ-B3525 in Subjects With Relapse/Refractory Diffuse Large B-cell Lymphoma （DLBCL）

Diffuse Large B-cell Lymphoma

China
Institute of Hematology & Blood Diseases Hospital
Cellular Biomedicine Group Ltd.

Completed

A Study of C-CAR066 in Subjects With r/r Diffuse Large B Cell Lymphoma Who Received CD19 CAR-T Therapy

Diffuse Large B Cell Lymphoma

China
Sun Yat-sen University

Unknown

Predictive Value of a mRNA Signature and Liquid Biopsy in Diffuse Large B Cell Lymphoma

Diffuse Large B Cell Lymphoma

China
Ruijin Hospital

Unknown

Lenalidomide Based Immunotherapy in the Treatment of DLBCL

Diffuse Large B Cell Lymphoma

China
Sinocelltech Ltd.

Unknown

A Study Comparing the Efficiency and Safety of S-CHOP(Cyclophosphamide, Hydroxydaunomycin, Oncovin, and Prednisone) Versus R-CHOP in Untreated CD20(Cluster of Differentiation Antigen 20)-Positive DLBCL Patients

Diffuse Large B Cell Lymphoma

China
Shanghai Ming Ju Biotechnology Co., Ltd.

Recruiting

CD19-targeted CAR T Cells for Relapsed and Refractory (R/R) Large B-cell Lymphoma

Lymphoma, Non-Hodgkin | Diffuse Large B Cell Lymphoma

China
Peng Liu

Recruiting

Prospective Clinical Study of ZPR Regimen in Relapsed/Refractory Diffuse Large B-cell Lymphoma

Diffuse Large B Cell Lymphoma

China
Ruijin Hospital

Recruiting

Biomarker Guided Treatment in DLBCL

Diffuse Large B Cell Lymphoma

China
Ruijin Hospital

Active, not recruiting

Reduced Chemotherapy in Low Risk DLBCL

Diffuse Large B-cell Lymphoma

China
Ruijin Hospital

Unknown

Decitabine Plus R-CHOP in Diffuse Large B-cell Lymphoma (DR-CHOP)

Diffuse Large B Cell Lymphoma

China
Ruijin Hospital

Unknown

Chidamide Plus R-CHOP in Elderly DLBCL

Diffuse Large B-cell Lymphoma

China
Ruijin Hospital

Unknown

A Study of Bortezomib Plus GDP in the Treatment of Refractory and Relapsed Non-GCB DLBCL

Diffuse Large B-cell Lymphoma

China
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

Withdrawn

Safety and Efficacy Study of CNOP Chemotherapy in Diffuse Large B Cell Lymphoma

Diffuse Large B Cell Lymphoma

China
Fudan University

Unknown

R-ESHAP Followed by Autologous Transplantation for Refractory or Relapsed Diffused Large B-cell Lymphoma

Diffuse Large B-cell Lymphoma

China
Anhui Provincial Hospital
Leman Biotech Co., Ltd

Recruiting

Safety and Efficacy of Metabolically Armed CD19 CAR-T Cells (Meta10-19) in the Treatment of r/r DLBCL Clinical Research

Diffuse Large B-cell Lymphoma

China
Jianfeng Zhou
CSPC Ouyi Pharmaceutical Co., Ltd.

Not yet recruiting

Mitoxantrone Hydrochloride Liposome Combined With Rituximab and Lenalidomide (M+R2) in Patients With Relapsed and Refractory Diffuse Large B-Cell Lymphoma

Diffuse Large B-cell Lymphoma

China
Zhejiang Cancer Hospital

Recruiting

ZR2 Followed by Immunochemotherapy in Elderly Patients With Newly-diagnosed DLBCL

Diffuse Large B Cell Lymphoma

China
The First Affiliated Hospital with Nanjing Medical...

Recruiting

Lenalidomide in Combination With R-GemOx in First-line Treatment of Elderly Diffuse Large B Cell Lymphoma

Diffuse Large B Cell Lymphoma

China
Fujian Medical University

Active, not recruiting

R-DA-EDOCH Versus R-CEOP90, With/Without Upfront Auto-HSCT in Young Patients With High-risk DLBCL

Diffuse Large B-cell Lymphoma

China
Chipscreen Biosciences, Ltd.

Active, not recruiting

Phase III Study of Tucidinostat in Combination With R-CHOP in Patients With Newly Diagnosed Double-Expressor DLBCL (DEB)

Diffuse Large B-cell Lymphoma

China
oubai

Unknown

Maintenance Therapy of Chidamide in Patients With HBV Positive Diffuse Large B-cell Lymphoma

Diffuse Large B-cell Lymphoma

China
First Affiliated Hospital of Zhejiang University

Unknown

An Exploratory Clinical Trial of Autologous Humanized Anti-cluster of Differentiation Antigen 19/20(CD19/CD20) Dual Specific CAR-T Cells Injection

Diffuse Large B Cell Lymphoma

China
The First Affiliated Hospital with Nanjing Medical...
Nanjing Bioheng Biotech Co., Ltd.

Unknown

CTA101 in the Treatment of Relapsed or Refractory Diffuse Large B-cell Lymphoma

Diffuse Large B-cell Lymphoma

China
Mingzhi Zhang

Unknown

A Clinical Trial of Decitabine in Relapse and Refractory Diffuse Large B Cell Lymphoma

Diffuse Large B Cell Lymphoma

China
Mingzhi Zhang

Unknown

Treatment of Elderly Patients With Diffuse Large B-cell Lymphoma

Diffuse Large B Cell Lymphoma

China
Xinjiang Medical University

Unknown

Cinobufacini Tablets Combined With Chemotherapeutic Protocol in Treatment of Diffuse Large B Cell Lymphoma

Diffuse, Large B-Cell, Lymphoma

China

Clinical Trials on Diffuse Large Cell Lymphoma in China

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Lebanon

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations